United States Drug Patent 8,802,714: Claim Scope, Tecovirimat Protection, Expiration and Patent Landscape

U.S. Patent No. 8,802,714 protects methods for treating or preventing orthopoxvirus infection with a defined mixture of two stereoisomeric compounds corresponding to tecovirimat, the active ingredient in TPOXX. The strongest claims require a composition containing approximately 95% or more of the principal stereoisomer, with claim 4 narrowing the mixture to approximately 98.5% of that stereoisomer and 1.5% of the second stereoisomer.

The patent is assigned to SIGA Technologies, Inc. It issued on Aug. 12, 2014, from a continuation application in a patent family directed to orthopoxvirus treatment. The reported expiration date is May 25, 2026, before any patent-term extension is considered. The patent’s principal commercial relevance is protection of tecovirimat treatment methods for smallpox and related orthopoxvirus infections, rather than broad protection of the tecovirimat molecule itself.

What drug does U.S. Patent 8,802,714 protect?

U.S. Patent 8,802,714 protects the use of a stereoisomeric mixture of tecovirimat-related compounds against orthopoxvirus infection.

The first compound in claim 1 is the principal active stereoisomer. The second is a related stereoisomer present in the product mixture. The claims do not use the generic name “tecovirimat”; they define the compounds by their complete chemical names and stereochemical configurations.

The protected mixture is characterized as follows:

Claim	Composition requirement	Legal effect
1	Mixture of the two specified compounds	Broadest independent method claim
2	At least about 95% by weight of the first compound	Narrows claim 1 by minimum purity
3	No more than about 5% by weight of the second compound	Alternative purity limitation
4	About 98.5% first compound and about 1.5% second compound	Most commercially specific composition claim
5	Living host is a mammal	Species limitation
6	Living host is a human	Human-treatment limitation
7	Broad list of orthopoxviruses	Pathogen limitation
8	Vaccinia, cowpox, smallpox, monkeypox or camelpox	Narrower virus list
9	About 0.125 to 250 mg/kg/day	Dose limitation
10	Pharmaceutically acceptable carrier	Formulation limitation
11-12	Combination with supplemental active agents	Combination-treatment limitations
13	Specified administration routes	Route limitation
14-15	Attenuated vaccinia strain, including variola-protective strains	Vaccine-related use limitations

The patent therefore covers a method of administering the defined mixture, not merely possessing the compound or manufacturing it.

What are the independent claims in U.S. Patent 8,802,714?

Claim 1 is the principal independent claim. It requires four elements:

A living host that has, or is susceptible to, an orthopoxvirus infection.
Treatment or prevention of that infection.
Administration of a therapeutically effective amount.
Administration of a mixture containing the two specified stereoisomeric compounds, or a pharmaceutically acceptable salt.

All other claims depend directly or indirectly on claim 1. This dependency materially limits the patent’s scope.

A party generally would not infringe claims 2 through 15 unless its conduct also satisfies claim 1. For example, a human-treatment product containing 98.5% of the principal stereoisomer may fall within claim 4, but only when used to treat or prevent an orthopoxvirus infection in the manner required by the claim.

How broad is claim 1?

Claim 1 is broad across several treatment variables but narrow as to chemical identity.

Chemical limitation

The claim requires both named compounds. A product containing only a different stereoisomer, a racemate with materially different composition, or a structurally distinct orthopox antiviral would not literally satisfy the mixture limitation.

The chemical definition is a strength for validity and enforcement because it identifies the compounds with precision. It is also a limitation because a competing product can attempt to avoid the claim by using a different stereoisomeric profile or a chemically distinct active ingredient.

Disease limitation

The claim covers infection caused by an orthopoxvirus and prevention in a host susceptible to infection. It is not limited to active smallpox disease. The claim reaches treatment or prevention involving the orthopoxvirus genus, subject to the claim’s other requirements.

Host limitation

The claim uses “living host,” which is broader than “human.” Dependent claims narrow the host to mammals and humans. The broad language potentially covers veterinary uses, laboratory-animal treatment and other mammalian applications, although commercial infringement analysis would depend on actual administration and product activity.

Dose limitation

Claim 1 does not specify a dose. Claim 9 adds a range of approximately 0.125 to 250 mg/kg/day. A use outside that range may remain within claim 1 if all other elements are satisfied.

Route limitation

Claim 1 does not restrict the administration route. Claim 13 identifies oral, rectal, parenteral, intracisternal, intravaginal, intraperitoneal, local and inhaled administration. Oral administration is commercially central for TPOXX, but the independent claim is not limited to oral delivery.

What formulations are protected by U.S. Patent 8,802,714?

The patent primarily protects the active stereoisomeric mixture as used in treatment. Claim 10 adds a pharmaceutically acceptable carrier medium, but it does not recite a specific tablet, capsule, excipient, dissolution profile or release mechanism.

This distinction matters:

A capsule containing the claimed mixture may satisfy claim 10 if used with a carrier.
A specific excipient system is not required by the claims.
The claims do not require a particular particle size, polymorph, salt form, coating or dissolution profile.
The claims do not expressly require the commercial TPOXX capsule formulation.
A formulation patent covering a specific dosage form could provide separate protection even if the product also falls within this patent.

The patent’s formulation scope is therefore functional and composition-oriented, rather than a detailed pharmaceutical-formulation claim set.

Does U.S. Patent 8,802,714 cover TPOXX?

Yes. TPOXX contains tecovirimat, also known as ST-246, and is approved by the FDA for treatment of human smallpox disease in adults and pediatric patients. The claimed stereoisomeric mixture corresponds to the tecovirimat active substance described in the patent family and related regulatory materials.

FDA approved TPOXX under the Animal Rule because controlled efficacy studies in humans were not feasible for smallpox. The approval applies to treatment of smallpox, not to every orthopoxvirus infection identified in claim 7. The broader patent claims can extend beyond the FDA-approved indication, but the approved label defines the regulated commercial use of TPOXX. [1]

The patent also covers prevention claims and attenuated-vaccinia-related embodiments that are broader than the current TPOXX smallpox treatment indication. Claim 15 requires an attenuated vaccinia strain that provides protective immunity against variola virus. That claim is directed to a prophylactic or vaccine-associated use and is not coextensive with the approved smallpox-treatment label.

When does U.S. Patent 8,802,714 expire?

The reported expiration date is May 25, 2026. The patent issued on Aug. 12, 2014, and claims priority through a family directed to orthopoxvirus treatment methods. Its term is tied to the applicable U.S. patent-family filing dates and statutory patent-term rules. [2]

Event	Date
Earliest relevant family priority	May 25, 2005
U.S. patent issued	Aug. 12, 2014
Reported patent expiration	May 25, 2026
FDA orphan exclusivity for TPOXX	July 13, 2025
Expected post-exclusivity patent period	July 14, 2025 to May 25, 2026

Patent expiration does not automatically authorize every competing product. Other patents, regulatory exclusivity, government procurement restrictions, patent litigation and separate formulation or manufacturing rights may affect launch timing.

What is the Orange Book status of TPOXX?

TPOXX is an FDA-approved drug product associated with NDA 208627. The Orange Book is the relevant FDA publication for approved drug products and listed patents. Patent listings for TPOXX have included SIGA patents directed to the active compound, methods of use and related product protection. [3]

The practical significance of U.S. Patent 8,802,714 depends on how it is listed against the approved drug and which claims correspond to the approved smallpox-treatment indication. A method-of-use patent can support a Paragraph IV certification or a section viii statement, depending on the patent listing and the applicant’s proposed labeling.

Orange Book analysis should distinguish among:

Drug-substance patents.
Drug-product or formulation patents.
Method-of-use patents.
Patents covering uses not included in the proposed generic label.
Patents that remain listed but do not block a product using a permitted carve-out.

The patent itself is not a broad composition-of-matter claim to every form of tecovirimat. Its commercial force is greatest when a proposed generic uses the claimed stereoisomeric mixture and carries labeling for treatment or prevention of an orthopoxvirus infection.

What Paragraph IV challenges and generic-entry risks exist?

A generic applicant seeking approval before the patent expiration date could take one of several positions:

Strategy	Relevant legal position	Risk profile
Wait for expiration	No early patent challenge	Lowest litigation exposure, delayed entry
Paragraph IV certification	Assert patent invalid, unenforceable or not infringed	High litigation exposure
Section viii carve-out	Remove patented method from labeling where permitted	Depends on Orange Book listing and practical use
Non-infringing formulation or stereochemical profile	Avoid the claimed mixture	Technical and equivalence risk
New chemical entity or alternative antiviral	Use a different active ingredient	No direct infringement of the chemical limitation

A Paragraph IV certification could trigger litigation under 21 U.S.C. § 271(e)(2) if the filing is directed to a product that would infringe the listed patent. The statutory 30-month stay mechanism under 21 U.S.C. § 355(j)(5)(B)(iii) could delay approval, subject to the patent-listing and litigation facts. [4]

The method claims create an important distinction. A generic applicant might seek approval for a label that omits the patented use. If the FDA permits a section viii carve-out and the resulting label does not encourage the patented use, the applicant may reduce infringement exposure. The risk remains higher if the generic is marketed for the same smallpox-treatment indication or if promotional materials encourage use within the patented claims.

Which companies are challenging the TPOXX patent estate?

Publicly available FDA and patent records do not establish a material, resolved Paragraph IV challenge specifically against U.S. Patent 8,802,714. SIGA’s principal commercial position remains tied to government procurement and stockpiling for smallpox preparedness, which differs from the conventional retail-generic market.

The absence of a publicly identified challenger does not eliminate future risk. Potential challengers could include generic manufacturers with capabilities in antiviral capsules, government-contract suppliers or companies developing alternative orthopoxvirus treatments. The commercial incentive is constrained by the narrow market, the absence of naturally occurring smallpox transmission and the dominance of government purchasing.

How does U.S. Patent 8,802,714 compare with other tecovirimat patents?

U.S. Patent 8,802,714 is one component of a broader SIGA patent estate.

Patent category	Typical subject matter	Strategic role
Early compound patents	Substituted bicyclic imides, including tecovirimat-related compounds	Core chemical protection
Orthopoxvirus method patents	Treatment or prevention using defined compounds	Use protection
Stereoisomer or mixture patents	Specified purity and isomer ratios	Product identity and quality protection
Formulation patents	Capsules, excipients, release or stability characteristics	Drug-product protection
Process patents	Preparation, purification or crystallization	Manufacturing barriers
Later continuation patents	Refined method, product or formulation claims	Layered exclusivity

The relevant competitive question is not whether one patent expires in 2026. It is whether a launch would satisfy the claims of the remaining family members and whether the product can be approved with a non-infringing label.

The early compound patent estate is older than the method patent estate and may have expired or approached expiration before the method claims. The later patents and continuations can preserve protection for particular products, formulations or manufacturing processes after an earlier compound patent expires.

How strong is the patent estate for tecovirimat?

The estate is commercially meaningful but technically concentrated.

Strengths

Claim 1 identifies the active stereoisomeric mixture with substantial chemical precision.
Claims cover treatment and prevention.
The virus definition includes smallpox, monkeypox, cowpox, vaccinia and camelpox.
Dependent claims cover humans, mammalian hosts, dosing, routes and combination therapy.
The claims map closely to the active ingredient used in TPOXX.
Government stockpiling creates a stable commercial market independent of ordinary retail demand.

Weaknesses

The patent does not broadly claim every orthopox antiviral.
The claims are method claims, requiring use or administration.
The composition limitation may permit design-around efforts involving a different stereoisomeric composition or active ingredient.
Claims 2 through 15 depend on claim 1 and inherit its limitations.
Claim 4’s “about 98.5%” and “about 1.5%” language may require fact-intensive analysis of measurement methods and claim construction.
Claims covering prevention, attenuated vaccinia and combination therapy may not correspond to the approved commercial label.

The strongest infringement case would involve a product containing the claimed tecovirimat mixture, marketed and administered to humans for smallpox or another listed orthopoxvirus indication before patent expiration.

What manufacturing and intellectual-property barriers remain?

A technically capable manufacturer would need to address more than the expired or expiring composition claims. Key barriers include:

Reproducing the required stereochemical composition.
Demonstrating pharmaceutical purity and stability.
Establishing bioequivalence or another FDA-acceptable approval basis.
Avoiding active process, crystallization and formulation patents.
Addressing Orange Book-listed method claims.
Securing access to validated manufacturing capacity.
Meeting government procurement and emergency-preparedness requirements.

The stereoisomer ratio in claim 4 is commercially relevant because a product that matches the TPOXX active ingredient profile may fall directly within the claim. A manufacturer that changes the ratio may face regulatory comparability issues even if it reduces literal infringement risk.

What is the litigation and settlement status?

No material final judgment or settlement specific to U.S. Patent 8,802,714 is identified in the supplied record. The patent remains relevant as an asserted or potentially assertable method patent until its reported expiration.

Any settlement involving an ANDA filer would require review of the complaint, patent numbers, proposed launch date, label restrictions and settlement terms. A settlement date alone would not establish the scope of the patent’s enforceable claims. Government contracts for TPOXX are also not equivalent to generic patent settlements because procurement agreements may operate independently of commercial ANDA litigation.

What generic launch scenarios exist after May 2026?

The most likely launch scenarios are:

Scenario	Timing	Commercial effect
No early challenge	After May 25, 2026	Entry after patent expiration, subject to other rights
Successful Paragraph IV defense	Before May 25, 2026	Potential early approval and launch
Section viii carve-out	Before expiration	Limited label and narrower infringement exposure
Additional formulation or process patents	After 2026	Delayed or restricted launch for specific product designs
Government-only market entry	After approval	Competition focused on federal stockpiles rather than retail sales

Generic competition may have limited effect on TPOXX revenue because sales are driven primarily by federal preparedness purchases. Revenue exposure is therefore concentrated in U.S. government contracts, strategic stockpiles and emergency procurement rather than routine prescriptions.

Key Takeaways

U.S. Patent 8,802,714 is a method-of-treatment patent for a defined tecovirimat stereoisomeric mixture.
Claim 1 requires administration of both specified compounds to treat or prevent orthopoxvirus infection.
Claim 4 is the most commercially specific claim, covering an approximately 98.5%/1.5% mixture.
Human treatment is expressly covered by claim 6, and smallpox, monkeypox, vaccinia and cowpox are included in claims 7 and 8.
The reported patent expiration date is May 25, 2026.
TPOXX was FDA-approved under the Animal Rule for treatment of human smallpox disease.
The patent does not independently protect every tecovirimat formulation or manufacturing process.
Generic entry could proceed through expiration, Paragraph IV litigation, a section viii carve-out or a non-infringing product design.
The principal commercial risk is layered protection from related compound, formulation, process and continuation patents rather than this patent alone.
The market is primarily government-driven, which may reduce the economic incentive for conventional generic competition.

FAQs About U.S. Patent 8,802,714

Does U.S. Patent 8,802,714 claim tecovirimat itself?

No. It claims methods that administer a defined mixture of two stereoisomeric compounds corresponding to tecovirimat-related active material. A separate composition-of-matter patent may provide broader chemical protection.

Does the patent cover monkeypox treatment?

Yes. Monkeypox virus is expressly listed in claim 7 and again within the narrower virus group in claim 8. The method must still satisfy the chemical, host and administration requirements of claim 1.

Is the patent limited to oral TPOXX capsules?

No. Claim 1 is not limited to oral delivery. Claim 13 identifies multiple administration routes, including oral, parenteral, rectal, intraperitoneal and inhaled administration.

Can a generic launch before May 25, 2026?

Potentially, but the applicant would need an approval strategy that addresses the patent, such as a successful Paragraph IV challenge, a permitted section viii carve-out or a product and label that do not infringe the listed claims.

Does FDA orphan exclusivity still block TPOXX competition?

TPOXX’s seven-year orphan-drug exclusivity period ran from its July 13, 2018 approval and expired in July 2025. Patent rights, Orange Book listings and other regulatory barriers must be analyzed separately.

References

U.S. Food and Drug Administration. (2018). TPOXX (tecovirimat) prescribing information. FDA.
U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,802,714, methods of treating orthopoxvirus infections. U.S. Department of Commerce.
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Code. (2025). 21 U.S.C. §§ 355 and 271(e)(2). United States Code.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1638938	⤷ Start Trial	301177	Netherlands	⤷ Start Trial
European Patent Office	1638938	⤷ Start Trial	2022C/521	Belgium	⤷ Start Trial
European Patent Office	1638938	⤷ Start Trial	122022000032	Germany	⤷ Start Trial
European Patent Office	1638938	⤷ Start Trial	2290024-5	Sweden	⤷ Start Trial
European Patent Office	1638938	⤷ Start Trial	C202230021	Spain	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,802,714

Summary for Patent: 8,802,714